Skip to main content
Zelluna ASA logo

Zelluna ASA — Investor Relations & Filings

Ticker · ULTI ISIN · NO0010851603 LEI · 254900B4VALJZR9TL744 OL Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2024-11-06 Interim / Quarterly Rep…
Country NO Norway
Listing OL ULTI

About Zelluna ASA

https://www.zelluna.com/

Zelluna ASA is a cell therapy company pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. The company's proprietary TCR-NK platform is designed to combine the high-precision targeting of TCRs with the potent, innate anti-tumor activity of NK cells. This approach aims to overcome the challenges associated with treating solid tumors. Zelluna is focused on creating a new generation of allogeneic, "off-the-shelf" cell therapies. The mission is to deliver transformative and potentially curative treatments for patients with advanced solid cancers, addressing a significant unmet medical need.

Recent filings

Filing Released Lang Actions
Ultimovacs ASA Reports Third Quarter 2024 Financial Results and Provides General Business Update
Interim / Quarterly Report Classification · 100% confidence The document is a 'Third Quarter 2024 Business Update' for Ultimovacs ASA. It contains a detailed operational review, CEO statement, and financial tables (Q3-24, YTD-24, and FY23 comparisons). It provides substantive financial data and analysis for the third quarter, which fits the definition of an Interim/Quarterly Report (IR). Q3 2024
2024-11-06 English
Ultimovacs ASA Reports Third Quarter 2024 Financial Results and Provides General Business Update
Earnings Release Classification · 100% confidence The document is titled "Ultimovacs ASA Reports Third Quarter 2024 Financial Results and Provides General Business Update." It explicitly details financial performance metrics for Q3 2024 (operating expenses, loss, cash flow) and provides a business update, including clinical trial progress. This content structure strongly indicates a comprehensive report covering a period shorter than a year, which aligns with the definition of an Interim/Quarterly Report (IR). Crucially, the text states: "The quarterly report and presentation will be published at 07:00 CET on November 6, 2024..." However, the document itself contains the detailed financial highlights and business updates, suggesting this text *is* the release accompanying the full report, or the report summary itself. Given the depth of financial figures (MNOK 28.8 expenses, MNOK 25.9 loss) and the specific mention of 'Third Quarter 2024 Financial Results,' it is more substantial than a mere 'Earnings Release' (ER) which usually contains only key highlights, and it is not just an announcement of a report (RPA). Therefore, the most appropriate classification is Interim / Quarterly Report (IR). Q3 2024
2024-11-06 English
Ultimovacs ASA: Invitation to third quarter 2024 results webcast presentation
Report Publication Announcement Classification · 98% confidence The document is a short announcement from Ultimovacs ASA inviting stakeholders to a webcast presentation for their third quarter 2024 results, scheduled for November 6, 2024. It explicitly states that the 'report and presentation will be available on the company website from 07:00 CET the same day.' Because the document itself is an invitation/announcement about the release of financial results and related materials, and it is very short (1243 characters), it fits the definition of a Report Publication Announcement (RPA) rather than the comprehensive Interim Report (IR) or Earnings Release (ER) itself. It announces the publication of the results materials.
2024-10-31 English
Ultimovacs Announces Publication of Phase II FOCUS Trial Results on medRxiv
Regulatory Filings Classification · 99% confidence The document is a press release titled "Ultimovacs Announces Publication of Phase II FOCUS Trial Results on medRxiv". It explicitly states that the results of a clinical trial have been published online on a preprint platform (medRxiv) and provides details about the trial's endpoints and findings. This structure—announcing the publication of specific data or results—fits the definition of a Report Publication Announcement (RPA), as it is not the full financial report (10-K, IR) or the initial earnings highlights (ER). Given the document's primary function is to announce the availability/publication of research results, RPA is the most appropriate classification, adhering to the 'MENU VS MEAL' rule.
2024-10-25 English
Ultimovacs Announces Patient Recruitment Discontinuation in LUNGVAC Trial Investigating UV1 Combined with Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer
Regulatory Filings Classification · 100% confidence The document is a press release from Ultimovacs ASA, dated September 11, 2024, announcing a specific operational update: the discontinuation of patient recruitment in the LUNGVAC clinical trial due to slow enrollment. It discusses clinical trial progress, expected data timelines (H1 2025), and mentions other ongoing trials (DOVACC) and technology development. This type of announcement, detailing specific operational or clinical milestones, is characteristic of a general regulatory filing or an announcement that doesn't fit the specific financial report categories (like 10-K, ER, or IR). Since it is a formal announcement of a material event that doesn't fit the more specific categories (like DIRS, DIV, CAP, etc.), the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements not covered elsewhere.
2024-09-11 English
Ultimovacs Announces Updated Data Analysis on UV1 Phase II NIPU Trial in Mesothelioma at ESMO 2024
Legal Proceedings Report Classification · 99% confidence The document is titled 'Ultimovacs Announces Updated Data Analysis on UV1 Phase II NIPU Trial in Mesothelioma at ESMO 2024' and details the presentation of clinical trial data at a medical conference (ESMO 2024). It discusses trial endpoints (PFS, ORR, OS), subgroup analysis, and future presentation plans. This content is characteristic of a press release announcing clinical or scientific updates, which often precedes or accompanies a formal regulatory filing or is released as a standalone update. Since it is an announcement of data being presented at a conference, and not a comprehensive financial report (10-K, IR) or a formal regulatory filing summary (RNS), it best fits the category for an announcement of scientific/clinical progress. However, none of the provided categories perfectly match 'Clinical Trial Update' or 'Press Release'. Given the options, this document is an announcement of company news regarding clinical data, which is often categorized broadly. It is not a formal financial report (10-K, IR), a management change (MANG), or a dividend notice (DIV). It is a specific announcement about research results. In the context of financial filings, such announcements are often classified as general Regulatory Filings (RNS) if they contain material non-public information, or sometimes as an Investor Presentation (IP) if it were the presentation itself, but here it is the *announcement* of the presentation. Since it is a material announcement about clinical data, and not a standard financial report, RNS (Regulatory Filings - general regulatory announcements and fallback) is the most appropriate general category, although it is very close to an Investor Presentation (IP) in content focus. Given the structure and purpose (announcing data presentation), RNS is the safest fallback for a material, non-standard financial announcement.
2024-09-08 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.